Nemaura Medical to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 14, 2021

Rhea-AI Summary

Nemaura Medical (NASDAQ: NMRD) announced participation at the Benzinga Global Small Cap Conference on May 14, 2021. CEO Faz Chowdhury will present at 3:15 PM ET. One-on-one meetings with Dr. Chowdhury can be arranged post-conference.

The company develops non-invasive wearable diagnostic devices, specifically sugarBEAT® and proBEAT™. With a focus on diabetes management, sugarBEAT® is a CE marked Class IIb medical device currently under FDA review. Nemaura operates in a market projected to exceed $59 billion by 2025 for Type 2 diabetes.

Loughborough, England, May 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that management will participate at the Benzinga Global Small Cap Conference on May 14, 2021.

Chief Executive Officer Faz Chowdhury, Ph.D. will deliver his corporate presentation at 3:15pm ET on May 14, 2021.

Investors can also request a one-on-one meeting with Dr. Chowdhury to be arranged following the conclusion of the conference.

Investors can register for the conference here: https://www.benzinga.com/events/small-cap/global/

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

FAQ

What is the Nemaura Medical presentation time at the Benzinga Global Small Cap Conference?

Nemaura Medical's CEO Faz Chowdhury will present at 3:15 PM ET on May 14, 2021.

How can investors meet with Nemaura Medical's CEO after the conference?

Investors can request a one-on-one meeting with CEO Faz Chowdhury to be arranged after the conference.

What products does Nemaura Medical focus on for diabetes management?

Nemaura Medical focuses on the non-invasive devices sugarBEAT® and proBEAT™ for diabetes management.

What market is Nemaura Medical targeting?

Nemaura Medical is targeting the Type 2 diabetes market, expected to reach nearly $59 billion by 2025.

What is the status of sugarBEAT® with the FDA?

Nemaura Medical has submitted a Premarket Approval Application (PMA) for sugarBEAT® to the U.S. FDA.